Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) from a sell rating to a hold rating in a research report sent to investors on Monday morning.

According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

Several other research firms also recently weighed in on AUPH. Canaccord Genuity reissued a buy rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Saturday, October 8th. FBR & Co set a $9.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, October 12th. HC Wainwright reissued a buy rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 5th. Leerink Swann reissued an outperform rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, October 3rd. Finally, Mackie reissued a buy rating and issued a $8.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $7.79.

Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 3.50 on Monday. The stock’s market cap is $139.04 million. Aurinia Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $5.69. The stock has a 50 day moving average of $3.58 and a 200-day moving average of $2.90.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Abingworth LLP increased its position in shares of Aurinia Pharmaceuticals by 479.8% in the second quarter. Abingworth LLP now owns 512,036 shares of the company’s stock worth $1,388,000 after buying an additional 423,729 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Aurinia Pharmaceuticals during the third quarter worth approximately $1,123,000. Redmile Group LLC increased its position in shares of Aurinia Pharmaceuticals by 560.4% in the third quarter. Redmile Group LLC now owns 187,610 shares of the company’s stock worth $565,000 after buying an additional 159,200 shares during the last quarter. Lombard Odier Asset Management USA Corp increased its position in shares of Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock worth $283,000 after buying an additional 2,813 shares during the last quarter. Finally, Creative Planning bought a new position in shares of Aurinia Pharmaceuticals during the third quarter worth approximately $181,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

5 Day Chart for NASDAQ:AUPH

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.